ABT

3 Back-of-the-Shelf Consumer Stocks With Growth and Income

These consumer stocks offer generous, growing dividends and should return to a growth trajectory based on new business lines.

3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories

The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.

5 Top Stock Trades for Thursday

A buyout for Ceasars? Earnings from Netflix, Abbott and Lam Research -- we've got it all covered in our top stock trades article.

ABT Stock Dips Following Q3 Earnings Results

ABT stock was down on Wednesday after the healthcare company released its earnings report for the third quarter of the year.

The 7 Best Long-Term Stocks for Risk-Off Investors

The short-term nature of the stock markets makes it hard for companies to think bigger picture -- but these seven best long-term stocks do. 

10 Dividend Aristocrats You Never Have to Worry About

There are dividend stocks, and then there are dividend aristocrats. These ten names are the income producers you rarely have to worry about.

RBC Capital Markets: 10 Leaders and Laggards for 2025

We take a closer look at 10 stocks RBC Capital has pinpointed as the leaders and laggards of the future. These are the stocks that are set to outperform in 2025, but also the stocks facing the biggest risks from our ever-changing society.

Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat

Abbott Laboratories (ABT) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018.

3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt

Stock charts of United Technologies, Abbott Laboratories and Leggett & Platt have earned a closer look as bullish trading prospects this morning.

Abbott Laboratories Stock Slips Despite Earnings Beat

Abbott Laboratories (ABT) stock as down on Wednesday despite the health care company reporting an earnings beat for the first quarter of 2018.

At $ 59.460, Abbott Laboratories (ABT) a Buy

The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and market intelligence.

Abbott Laboratories (ABT) a Buy This Week

The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and news.

5 Cheap Dividend Stocks With Growing Payouts

With interest rates still low and the market possibly overvalued, cheap dividend stocks are a good choice for retirement and income investors.

7 ‘Strong Buy’ Stocks That Look Cheap Right Now

With recent market fluctuations, these 7 stocks now make particularly compelling investing opportunities -- and each boasts a Street consensus rating of 'Strong Buy.'

Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings Momentum

Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.

5 Soaring ‘Strong Buy’ Stocks Ahead of Earnings Season

Here are five stellar stocks to keep a close eye on as we head deeper into earnings season. All these stocks are due to report earnings in the next couple of weeks. You can feel good about these stock picks as each of these five stocks has a 'Strong Buy' consensus rating from the Street's best-performing analysts.

3 of the Best Dividend Aristocrats for Retirement

Dividend Aristocrats are some of the most reliable dividend stocks out there. But these specific "aristocrats" offer both growth and income.

AbbVie Inc Dividend at Risk Amid Patent Protection Problems

ABBV remains a strong holding for dividend growth, but AbbVie is about to lose patent protection on Humira, which accounts for two-thirds of its revenue.

Abbott Laboratories (ABT) a Buy on Strong Earnings Momentum

The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) has been derived by using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 3 months.